Venkata S Sabbisetti, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 16 | 2022 | 1942 | 0.770 |
Why?
|
Renal Insufficiency, Chronic | 13 | 2023 | 2298 | 0.710 |
Why?
|
Renal Insufficiency | 3 | 2015 | 812 | 0.650 |
Why?
|
Receptors, Virus | 9 | 2015 | 652 | 0.600 |
Why?
|
Membrane Glycoproteins | 9 | 2015 | 3711 | 0.580 |
Why?
|
Glomerular Filtration Rate | 11 | 2021 | 2227 | 0.490 |
Why?
|
Kidney Failure, Chronic | 8 | 2021 | 2496 | 0.490 |
Why?
|
Calcitonin | 2 | 2006 | 328 | 0.470 |
Why?
|
Lipocalins | 6 | 2014 | 161 | 0.440 |
Why?
|
Membrane Proteins | 5 | 2015 | 7876 | 0.440 |
Why?
|
Diabetic Nephropathies | 5 | 2021 | 973 | 0.430 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 547 | 0.430 |
Why?
|
Kidney Neoplasms | 6 | 2024 | 4282 | 0.430 |
Why?
|
Kidney Tubules, Proximal | 7 | 2021 | 386 | 0.420 |
Why?
|
Liposomes | 1 | 2016 | 790 | 0.400 |
Why?
|
Kidney | 12 | 2023 | 7064 | 0.390 |
Why?
|
Cystatin C | 4 | 2018 | 272 | 0.360 |
Why?
|
Acute-Phase Proteins | 5 | 2014 | 252 | 0.340 |
Why?
|
Kidney Tubules | 4 | 2021 | 454 | 0.330 |
Why?
|
Creatinine | 10 | 2021 | 1918 | 0.320 |
Why?
|
Acetylglucosaminidase | 4 | 2018 | 66 | 0.320 |
Why?
|
Carcinoma, Renal Cell | 6 | 2024 | 3187 | 0.300 |
Why?
|
Cell Adhesion Molecules | 1 | 2014 | 1613 | 0.290 |
Why?
|
Neoplasm Invasiveness | 2 | 2006 | 3620 | 0.290 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2006 | 324 | 0.240 |
Why?
|
Chemokine CCL2 | 3 | 2021 | 605 | 0.230 |
Why?
|
Albuminuria | 6 | 2021 | 658 | 0.230 |
Why?
|
Nanoparticles | 4 | 2016 | 1985 | 0.220 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 481 | 0.210 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 2 | 2020 | 257 | 0.200 |
Why?
|
Endothelin-1 | 2 | 2021 | 296 | 0.200 |
Why?
|
Alpha-Globulins | 1 | 2021 | 26 | 0.190 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 2 | 2020 | 348 | 0.190 |
Why?
|
Antineoplastic Agents | 4 | 2016 | 13676 | 0.180 |
Why?
|
Fatty Acid-Binding Proteins | 3 | 2017 | 293 | 0.180 |
Why?
|
Fibroblast Growth Factors | 2 | 2016 | 873 | 0.170 |
Why?
|
Cells | 1 | 2021 | 166 | 0.170 |
Why?
|
Diuretics, Osmotic | 1 | 2019 | 32 | 0.160 |
Why?
|
Pericytes | 1 | 2022 | 299 | 0.160 |
Why?
|
Disease Progression | 7 | 2021 | 13671 | 0.160 |
Why?
|
Reperfusion Injury | 3 | 2015 | 1039 | 0.160 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2023 | 638 | 0.160 |
Why?
|
Epidermal Growth Factor | 1 | 2021 | 697 | 0.160 |
Why?
|
Mannitol | 1 | 2019 | 176 | 0.150 |
Why?
|
Diet, Gluten-Free | 1 | 2021 | 284 | 0.150 |
Why?
|
Proto-Oncogene Proteins | 5 | 2014 | 4528 | 0.150 |
Why?
|
Diuresis | 1 | 2018 | 107 | 0.150 |
Why?
|
Dairy Products | 1 | 2021 | 490 | 0.150 |
Why?
|
STAT3 Transcription Factor | 1 | 2022 | 874 | 0.140 |
Why?
|
Transforming Growth Factor alpha | 1 | 2017 | 134 | 0.140 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 794 | 0.140 |
Why?
|
Nephrotic Syndrome | 1 | 2021 | 381 | 0.140 |
Why?
|
Renal Dialysis | 4 | 2021 | 1791 | 0.140 |
Why?
|
Fibrosis | 6 | 2023 | 2080 | 0.140 |
Why?
|
Hemopexin | 1 | 2016 | 33 | 0.140 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2018 | 158 | 0.130 |
Why?
|
Monitoring, Immunologic | 1 | 2016 | 100 | 0.130 |
Why?
|
Meclizine | 1 | 2015 | 13 | 0.130 |
Why?
|
Chromium | 1 | 2016 | 133 | 0.130 |
Why?
|
Fluorocarbons | 1 | 2021 | 506 | 0.120 |
Why?
|
Prospective Studies | 18 | 2024 | 54926 | 0.120 |
Why?
|
Haptoglobins | 1 | 2016 | 165 | 0.120 |
Why?
|
Carcinogens, Environmental | 1 | 2015 | 70 | 0.120 |
Why?
|
Male | 44 | 2024 | 364719 | 0.120 |
Why?
|
Ischemic Preconditioning | 1 | 2015 | 89 | 0.120 |
Why?
|
Interdisciplinary Studies | 1 | 2015 | 86 | 0.120 |
Why?
|
Angiotensins | 1 | 2015 | 141 | 0.120 |
Why?
|
Protective Agents | 1 | 2015 | 150 | 0.110 |
Why?
|
Hazardous Substances | 1 | 2015 | 153 | 0.110 |
Why?
|
Drug Carriers | 2 | 2016 | 709 | 0.110 |
Why?
|
Hyperbaric Oxygenation | 1 | 2015 | 166 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 4058 | 0.110 |
Why?
|
Cardiopulmonary Bypass | 1 | 2018 | 1097 | 0.110 |
Why?
|
Prostatic Neoplasms | 2 | 2006 | 11101 | 0.110 |
Why?
|
Fatty Acids | 1 | 2021 | 1812 | 0.110 |
Why?
|
Hypotension | 1 | 2019 | 888 | 0.100 |
Why?
|
Cell Line, Tumor | 6 | 2017 | 17140 | 0.100 |
Why?
|
Aristolochic Acids | 1 | 2012 | 13 | 0.100 |
Why?
|
Neoplasms | 6 | 2017 | 22371 | 0.100 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2013 | 105 | 0.100 |
Why?
|
Arsenic | 1 | 2016 | 358 | 0.100 |
Why?
|
Epithelial Cells | 4 | 2015 | 3703 | 0.100 |
Why?
|
Trichloroethylene | 1 | 2012 | 13 | 0.100 |
Why?
|
Lithotripsy | 1 | 2013 | 137 | 0.100 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 6231 | 0.100 |
Why?
|
Specimen Handling | 2 | 2015 | 708 | 0.100 |
Why?
|
Ureteroscopy | 1 | 2013 | 140 | 0.100 |
Why?
|
beta 2-Microglobulin | 1 | 2013 | 330 | 0.100 |
Why?
|
Quality Control | 1 | 2015 | 836 | 0.100 |
Why?
|
RNA, Transfer | 1 | 2014 | 284 | 0.100 |
Why?
|
Macrophage Activation | 1 | 2015 | 557 | 0.100 |
Why?
|
Tissue Distribution | 1 | 2016 | 2300 | 0.100 |
Why?
|
Aminoglycosides | 1 | 2012 | 161 | 0.100 |
Why?
|
Humans | 52 | 2024 | 768166 | 0.100 |
Why?
|
Limit of Detection | 1 | 2012 | 277 | 0.100 |
Why?
|
Case-Control Studies | 8 | 2018 | 22291 | 0.090 |
Why?
|
Acetaminophen | 1 | 2015 | 552 | 0.090 |
Why?
|
Nephrectomy | 3 | 2024 | 930 | 0.090 |
Why?
|
Platinum | 1 | 2012 | 222 | 0.090 |
Why?
|
Indians, North American | 1 | 2014 | 354 | 0.090 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2011 | 89 | 0.090 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2020 | 75 | 0.090 |
Why?
|
Renin-Angiotensin System | 1 | 2015 | 737 | 0.090 |
Why?
|
Kidney Function Tests | 1 | 2012 | 684 | 0.090 |
Why?
|
Fontan Procedure | 1 | 2016 | 805 | 0.090 |
Why?
|
Female | 35 | 2024 | 397192 | 0.090 |
Why?
|
Glomerulonephritis | 1 | 2012 | 333 | 0.080 |
Why?
|
Drug Monitoring | 1 | 2016 | 964 | 0.080 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 719 | 0.080 |
Why?
|
Myristic Acids | 1 | 2009 | 49 | 0.080 |
Why?
|
Nitric Oxide | 1 | 2018 | 2146 | 0.080 |
Why?
|
Biological Assay | 1 | 2012 | 628 | 0.080 |
Why?
|
Codon, Nonsense | 1 | 2011 | 287 | 0.080 |
Why?
|
Kidney Calculi | 1 | 2013 | 458 | 0.080 |
Why?
|
Phagocytosis | 1 | 2015 | 1530 | 0.080 |
Why?
|
Middle Aged | 23 | 2024 | 223492 | 0.080 |
Why?
|
Aged | 20 | 2024 | 171504 | 0.080 |
Why?
|
Cell Communication | 1 | 2015 | 1660 | 0.080 |
Why?
|
Animals | 17 | 2022 | 169246 | 0.080 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1566 | 0.070 |
Why?
|
Genome, Human | 1 | 2021 | 4446 | 0.070 |
Why?
|
Mice, Inbred C57BL | 8 | 2022 | 22379 | 0.070 |
Why?
|
Apoptosis | 6 | 2016 | 9523 | 0.070 |
Why?
|
ROC Curve | 3 | 2024 | 3628 | 0.070 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2232 | 0.070 |
Why?
|
Nephritis | 2 | 2021 | 147 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2418 | 0.070 |
Why?
|
Cell Survival | 3 | 2016 | 5777 | 0.070 |
Why?
|
Environmental Pollutants | 1 | 2016 | 1296 | 0.070 |
Why?
|
Inflammation | 4 | 2020 | 10873 | 0.070 |
Why?
|
Gelatinases | 1 | 2006 | 93 | 0.070 |
Why?
|
Oxidative Stress | 2 | 2015 | 3139 | 0.070 |
Why?
|
Proportional Hazards Models | 5 | 2020 | 12543 | 0.070 |
Why?
|
Receptors, Calcitonin | 1 | 2005 | 34 | 0.070 |
Why?
|
Prognosis | 7 | 2024 | 30010 | 0.060 |
Why?
|
Disease Models, Animal | 4 | 2015 | 18349 | 0.060 |
Why?
|
Kidney Diseases | 2 | 2016 | 2100 | 0.060 |
Why?
|
LLC-PK1 Cells | 2 | 2015 | 125 | 0.060 |
Why?
|
Neoplasm Proteins | 2 | 2014 | 3603 | 0.060 |
Why?
|
Mice | 10 | 2022 | 82029 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2018 | 15832 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2015 | 4912 | 0.060 |
Why?
|
Urinalysis | 2 | 2017 | 370 | 0.060 |
Why?
|
Protein Isoforms | 1 | 2009 | 1715 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2016 | 5341 | 0.060 |
Why?
|
Endothelium, Vascular | 1 | 2015 | 4427 | 0.050 |
Why?
|
Environmental Exposure | 2 | 2016 | 4543 | 0.050 |
Why?
|
Time Factors | 7 | 2021 | 40218 | 0.050 |
Why?
|
Matrix Metalloproteinases | 1 | 2005 | 393 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6847 | 0.050 |
Why?
|
Cholesterol | 1 | 2012 | 2914 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 1 | 2014 | 8128 | 0.050 |
Why?
|
Liver Transplantation | 1 | 2015 | 2401 | 0.050 |
Why?
|
Risk | 3 | 2021 | 9613 | 0.050 |
Why?
|
Endothelial Cells | 1 | 2015 | 3589 | 0.050 |
Why?
|
Gene Silencing | 1 | 2009 | 1505 | 0.050 |
Why?
|
Hospitalization | 2 | 2020 | 10840 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39348 | 0.050 |
Why?
|
Young Adult | 7 | 2021 | 60066 | 0.050 |
Why?
|
Adult | 14 | 2024 | 223646 | 0.050 |
Why?
|
Occupational Exposure | 1 | 2012 | 1807 | 0.050 |
Why?
|
Mice, Knockout | 4 | 2022 | 14488 | 0.050 |
Why?
|
Hypertension | 1 | 2021 | 8616 | 0.050 |
Why?
|
Predictive Value of Tests | 4 | 2024 | 15454 | 0.050 |
Why?
|
Cell Cycle | 1 | 2009 | 2932 | 0.050 |
Why?
|
Cell Transdifferentiation | 1 | 2022 | 186 | 0.050 |
Why?
|
Palmitic Acid | 1 | 2021 | 149 | 0.040 |
Why?
|
Diabetes Mellitus, Experimental | 2 | 2021 | 1124 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2015 | 12252 | 0.040 |
Why?
|
Serum Albumin, Bovine | 1 | 2021 | 320 | 0.040 |
Why?
|
Cardiac Surgical Procedures | 1 | 2016 | 3683 | 0.040 |
Why?
|
Cohort Studies | 6 | 2021 | 41754 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2021 | 3428 | 0.040 |
Why?
|
Atherosclerosis | 2 | 2015 | 3433 | 0.040 |
Why?
|
Heart Defects, Congenital | 1 | 2016 | 4712 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2014 | 3447 | 0.040 |
Why?
|
Hypertonic Solutions | 1 | 2019 | 82 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2017 | 15662 | 0.040 |
Why?
|
Inflammation Mediators | 2 | 2021 | 1892 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 1 | 2009 | 2810 | 0.040 |
Why?
|
Area Under Curve | 2 | 2015 | 1643 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 2006 | 6124 | 0.040 |
Why?
|
Sulfones | 1 | 2021 | 448 | 0.040 |
Why?
|
Risk Assessment | 5 | 2018 | 24315 | 0.040 |
Why?
|
Phosphorylation | 1 | 2009 | 8317 | 0.040 |
Why?
|
DNA Damage | 2 | 2021 | 2469 | 0.040 |
Why?
|
Vasoconstrictor Agents | 1 | 2021 | 656 | 0.040 |
Why?
|
Models, Biological | 2 | 2016 | 9495 | 0.040 |
Why?
|
Free Radical Scavengers | 1 | 2018 | 213 | 0.040 |
Why?
|
Cytokines | 3 | 2021 | 7453 | 0.040 |
Why?
|
Aged, 80 and over | 4 | 2018 | 59629 | 0.040 |
Why?
|
Cisplatin | 2 | 2015 | 1660 | 0.040 |
Why?
|
Adolescent | 7 | 2021 | 89169 | 0.030 |
Why?
|
Hexosaminidases | 1 | 2016 | 45 | 0.030 |
Why?
|
Sodium-Phosphate Cotransporter Proteins, Type IIb | 1 | 2016 | 10 | 0.030 |
Why?
|
Boston | 2 | 2021 | 9374 | 0.030 |
Why?
|
Endocytosis | 1 | 2021 | 956 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8741 | 0.030 |
Why?
|
Treatment Outcome | 6 | 2021 | 65371 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2015 | 1656 | 0.030 |
Why?
|
Esterases | 1 | 2016 | 89 | 0.030 |
Why?
|
Jurkat Cells | 1 | 2017 | 740 | 0.030 |
Why?
|
Sodium Cyanide | 1 | 2015 | 9 | 0.030 |
Why?
|
Fluorides | 1 | 2016 | 134 | 0.030 |
Why?
|
Child | 6 | 2021 | 80917 | 0.030 |
Why?
|
Goals | 1 | 2021 | 717 | 0.030 |
Why?
|
Algorithms | 1 | 2016 | 14164 | 0.030 |
Why?
|
Benzamides | 1 | 2021 | 1379 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6526 | 0.030 |
Why?
|
Radiation Chimera | 1 | 2015 | 216 | 0.030 |
Why?
|
Swine | 2 | 2015 | 5995 | 0.030 |
Why?
|
Ethanolamines | 1 | 2015 | 152 | 0.030 |
Why?
|
Cytochromes c | 1 | 2015 | 173 | 0.030 |
Why?
|
Cell Respiration | 1 | 2015 | 201 | 0.030 |
Why?
|
Autophagy | 1 | 2023 | 1349 | 0.030 |
Why?
|
Deoxyglucose | 1 | 2015 | 333 | 0.030 |
Why?
|
Signal Transduction | 3 | 2022 | 23645 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 791 | 0.030 |
Why?
|
Shock, Hemorrhagic | 1 | 2016 | 224 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1625 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2009 | 5804 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20227 | 0.030 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2015 | 412 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12077 | 0.030 |
Why?
|
Galactose | 1 | 2015 | 300 | 0.030 |
Why?
|
Mice, Obese | 1 | 2015 | 417 | 0.030 |
Why?
|
Cardiac Output | 1 | 2016 | 838 | 0.030 |
Why?
|
Mexico | 1 | 2016 | 769 | 0.030 |
Why?
|
Child, Preschool | 4 | 2021 | 42669 | 0.030 |
Why?
|
Caspase 3 | 1 | 2016 | 730 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7477 | 0.030 |
Why?
|
Pulmonary Circulation | 1 | 2016 | 745 | 0.030 |
Why?
|
Nanomedicine | 1 | 2016 | 292 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11879 | 0.030 |
Why?
|
Molecular Dynamics Simulation | 1 | 2016 | 427 | 0.030 |
Why?
|
Risk Factors | 5 | 2020 | 74944 | 0.030 |
Why?
|
Sweden | 1 | 2016 | 1382 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1622 | 0.030 |
Why?
|
Serum Albumin | 1 | 2016 | 677 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2014 | 540 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2018 | 2923 | 0.030 |
Why?
|
RNA Interference | 1 | 2021 | 2832 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3556 | 0.030 |
Why?
|
Phosphates | 1 | 2016 | 765 | 0.020 |
Why?
|
Intestines | 1 | 2021 | 1909 | 0.020 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2013 | 283 | 0.020 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2012 | 107 | 0.020 |
Why?
|
Nephrolithiasis | 1 | 2013 | 117 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2009 | 9615 | 0.020 |
Why?
|
Resuscitation | 1 | 2016 | 679 | 0.020 |
Why?
|
Succinic Acid | 1 | 2012 | 86 | 0.020 |
Why?
|
Gentamicins | 1 | 2012 | 244 | 0.020 |
Why?
|
Inhibitory Concentration 50 | 1 | 2012 | 464 | 0.020 |
Why?
|
Blood Pressure | 2 | 2021 | 8543 | 0.020 |
Why?
|
Nanostructures | 1 | 2016 | 553 | 0.020 |
Why?
|
Mice, 129 Strain | 1 | 2012 | 369 | 0.020 |
Why?
|
Glycolysis | 1 | 2015 | 837 | 0.020 |
Why?
|
Critical Illness | 2 | 2016 | 2756 | 0.020 |
Why?
|
Absorption | 1 | 2011 | 244 | 0.020 |
Why?
|
Blood Proteins | 1 | 2016 | 1191 | 0.020 |
Why?
|
Streptozocin | 1 | 2011 | 190 | 0.020 |
Why?
|
Extracellular Matrix Proteins | 1 | 2015 | 832 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2005 | 12800 | 0.020 |
Why?
|
gamma-Glutamyltransferase | 1 | 2011 | 144 | 0.020 |
Why?
|
Infant | 3 | 2021 | 36535 | 0.020 |
Why?
|
Ligands | 1 | 2017 | 3284 | 0.020 |
Why?
|
Oligopeptides | 1 | 2016 | 1194 | 0.020 |
Why?
|
Lead | 1 | 2016 | 882 | 0.020 |
Why?
|
Coronary Circulation | 1 | 2016 | 1617 | 0.020 |
Why?
|
Models, Chemical | 1 | 2012 | 611 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2013 | 9561 | 0.020 |
Why?
|
Rats, Wistar | 1 | 2014 | 1888 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2021 | 5315 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1906 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2010 | 363 | 0.020 |
Why?
|
Japan | 1 | 2014 | 1418 | 0.020 |
Why?
|
Mice, Inbred C3H | 1 | 2011 | 915 | 0.020 |
Why?
|
Phenotype | 2 | 2020 | 16726 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6793 | 0.020 |
Why?
|
Interleukin-18 | 1 | 2011 | 251 | 0.020 |
Why?
|
United States | 4 | 2021 | 73039 | 0.020 |
Why?
|
Adenosine | 1 | 2014 | 820 | 0.020 |
Why?
|
Parathyroid Hormone | 1 | 2016 | 1804 | 0.020 |
Why?
|
Podocytes | 1 | 2013 | 403 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2015 | 3096 | 0.020 |
Why?
|
Adenosine Triphosphate | 1 | 2015 | 2004 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1752 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2016 | 2633 | 0.020 |
Why?
|
Polymers | 1 | 2016 | 1630 | 0.020 |
Why?
|
Pyrroles | 1 | 2015 | 1124 | 0.020 |
Why?
|
Paclitaxel | 1 | 2016 | 1733 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 3772 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2016 | 1930 | 0.020 |
Why?
|
Sirolimus | 1 | 2015 | 1540 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2011 | 1754 | 0.020 |
Why?
|
Intensive Care Units, Pediatric | 1 | 2014 | 1027 | 0.020 |
Why?
|
Models, Genetic | 1 | 2017 | 3447 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2021 | 3114 | 0.020 |
Why?
|
Acute Disease | 1 | 2018 | 7243 | 0.020 |
Why?
|
Indoles | 1 | 2015 | 1836 | 0.020 |
Why?
|
Nanotechnology | 1 | 2012 | 714 | 0.020 |
Why?
|
Reference Values | 1 | 2014 | 4938 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2012 | 2065 | 0.020 |
Why?
|
NF-kappa B | 1 | 2015 | 2493 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3814 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3721 | 0.020 |
Why?
|
Up-Regulation | 1 | 2015 | 4146 | 0.020 |
Why?
|
China | 1 | 2012 | 2395 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 2429 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2013 | 1738 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2885 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12465 | 0.010 |
Why?
|
Length of Stay | 1 | 2018 | 6498 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11095 | 0.010 |
Why?
|
Graft Survival | 1 | 2015 | 3887 | 0.010 |
Why?
|
Sex Factors | 1 | 2018 | 10632 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4568 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2018 | 3239 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15869 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2018 | 11244 | 0.010 |
Why?
|
Regeneration | 1 | 2012 | 1524 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4035 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2015 | 3080 | 0.010 |
Why?
|
Infant, Premature | 1 | 2012 | 2124 | 0.010 |
Why?
|
Vitamin D | 1 | 2016 | 3311 | 0.010 |
Why?
|
Mitochondria | 1 | 2015 | 3681 | 0.010 |
Why?
|
Genomics | 1 | 2017 | 5926 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18412 | 0.010 |
Why?
|
Survival Rate | 1 | 2015 | 12840 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2016 | 19015 | 0.010 |
Why?
|
Logistic Models | 1 | 2015 | 13290 | 0.010 |
Why?
|
MicroRNAs | 1 | 2016 | 3803 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26379 | 0.010 |
Why?
|
Biomedical Research | 1 | 2015 | 3463 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 8054 | 0.010 |
Why?
|
Glucose | 1 | 2011 | 4352 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15948 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 11928 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10474 | 0.010 |
Why?
|
Incidence | 1 | 2014 | 21538 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4262 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2012 | 26422 | 0.010 |
Why?
|